Dr. Yu is an expert in DNA recombineering (Lambda-Red, CRISPR), Salmonella engineering, and bacterial-based cancer imm​unotherapy. Dr. Yu earned his BS degree from Shandong University, Jinan and Master degree from Sun Yat-Sen University, Guangzhou. Then, he went to Hong Kong to pursue his PhD study in Salmonella engineering.He earned his PhD degree from the University of Hong Kong in 2012. Thereafter, Dr. Yu received his postdoctoral training in Cancer immunotherapy, and focus on pet animalcancer therapy and animal welfare. Dr. Yu is the Inventor of YB1, and its named after him. YB1 stands not only for the first generation of engineered Salmonellafor immunotherapy, but also the top one technology in synthetic biology. His works in YB1 has been granted with US, EU, and CN patents.
 Dr. Yu Bin  Founder &CEO  Inventor of YB1
Prof. Huang is an expert in bacterial-based cancer immunotherapy. Prof. Huang earned his BS degree from Fudan University, Shanghai and went to the US through the CUSBEA program to pursue his PhD study in transcriptional regulation during fruit fly embryonic pattern formation. He earned his PhD degree from the University of California, Los Angeles. Thereafter, Prof. Huang received his postdoctoral training in mouse genetics at National Cancer Institute, NIH in the USA. During this period, Prof. Huang was the first to report that the two major intracellular transportation systems of mammalian cells, the microtubule- and actin-filament-based system directly interact with each other through their motor proteins, kinesin and myosin. He established his own laboratory at the University of Hong Kong. Prof. Huang is now an endowed professor in the School of Biomedical Sciences, the University of Hong Kong.​
 Prof. Huang Jiandong  Co-funder& advisor  Inventor of YB1
Ms. Huang is specialized in designing and conducting clinical trials. She brings her life sciences experience to the BACMUNO team, and is responsible for leading operations with a focus on overseeing clinical development programs and managing early commercial planning activities. As the GCP license holder, she has been working in Queen Mary Hospital, Hong Kong for many years, and leading multiple industrial clinical trial projects. She also worked with Clinical Trial Centre the University of Hong Kong and China Food and Drug Administration(CFDA).

Ms. Huang obtained Master of Public Health degree with distinction from the University of Hong Kong, Bachelor of Medicine and Bachelor of Science in the Southern Medical University. She was an clinical pharmacist in the Guangdong General Hospital. She is interested and specialized in commercialized lab innovation drugs.
Ms. Huang Yuan, MPH  COO& Clinical Program Director